Vitalink Research-Gaffney — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$7,201	143
2024	Research	$10,711	2
2023	Research	$4,518	2
2020	Research	$7,323	2

Breakdown

Who paid Research payments · program years 2020–2025

Boehringer Ingelheim International GmbH $19,535 144 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $10,219 5 payments

Studies the money was for Research payments · program years 2020–2025

Obesity Long term safety in patients with CV risk $15,229 4 payments
Tio & Olo versus PBO stratified by PIFR $7,323 2 payments
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $7,201 143 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.